Development of a topical bacteriophage gel targeting Cutibacterium acnes for acne prone skin and results of a phase 1 cosmetic randomized clinical trial
Abstract Background Topical antibiotics are frequently used to treat acne vulgaris. Their prolonged use, often for longer durations than recommended, has led to antibiotic resistance in Cutibacterium acnes (C. acnes), a bacterium implicated in acne pathophysiology. Bacteriophage (phage), which speci...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-06-01
|
| Series: | Skin Health and Disease |
| Online Access: | https://doi.org/10.1002/ski2.93 |
| _version_ | 1811337293252788224 |
|---|---|
| author | M. Golembo S. Puttagunta U. Rappo E. Weinstock R. Engelstein I. Gahali‐Sass A. Moses E. Kario E. Ben‐Dor Cohen J. Nicenboim H. Ben David K. Sudakov A. Cohen M. Bassan N. B. Zak |
| author_facet | M. Golembo S. Puttagunta U. Rappo E. Weinstock R. Engelstein I. Gahali‐Sass A. Moses E. Kario E. Ben‐Dor Cohen J. Nicenboim H. Ben David K. Sudakov A. Cohen M. Bassan N. B. Zak |
| author_sort | M. Golembo |
| collection | DOAJ |
| description | Abstract Background Topical antibiotics are frequently used to treat acne vulgaris. Their prolonged use, often for longer durations than recommended, has led to antibiotic resistance in Cutibacterium acnes (C. acnes), a bacterium implicated in acne pathophysiology. Bacteriophage (phage), which specifically target C. acnes by a different mechanism of action and do not harm potentially beneficial bacteria, may offer an alternative approach for improvement of the appearance of acne prone skin. Objectives To identify and characterize C. acnes targeting phage, carry out a comprehensive preclinical safety evaluation of phages selected for further development and examine their safety, tolerability and ability to target facial C. acnes when applied topically in a cosmetic clinical study including participants with mild‐to‐moderate acne. Methods Phages were isolated by conventional microbiological methods also used to examine their breadth of host range on different C. acnes strains and specificity to this bacterial species. Safety assessment of three selected phages was carried out by complete genomic analysis to assure the absence of undesired sequences and by ex vivo models employed to evaluate the safety, irritability and potential systemic bioavailability of phage applied topically. A randomized, controlled clinical study assessed safety, tolerability and efficacy in targeting facial C. acnes. Results Wide host range phages that also target antibiotic resistant C. acnes were identified. Their genomes were shown to be free of undesired genes. The three‐phage cocktail, BX001, was not irritant to human skin or ocular tissues in ex vivo models and did not permeate through human epidermis. In a cosmetic clinical study, topically applied BX001 was safe and well tolerated and reduced the facial burden of C. acnes. Conclusions Combined in silico and ex vivo approaches successfully predicted the observed safety and efficacy of C. acnes targeting phage when these were topically administered in a well‐controlled cosmetic clinical study. |
| first_indexed | 2024-04-13T17:52:42Z |
| format | Article |
| id | doaj.art-c7689b1234794b20bafbb53c4fe4260e |
| institution | Directory Open Access Journal |
| issn | 2690-442X |
| language | English |
| last_indexed | 2024-04-13T17:52:42Z |
| publishDate | 2022-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | Skin Health and Disease |
| spelling | doaj.art-c7689b1234794b20bafbb53c4fe4260e2022-12-22T02:36:39ZengWileySkin Health and Disease2690-442X2022-06-0122n/an/a10.1002/ski2.93Development of a topical bacteriophage gel targeting Cutibacterium acnes for acne prone skin and results of a phase 1 cosmetic randomized clinical trialM. Golembo0S. Puttagunta1U. Rappo2E. Weinstock3R. Engelstein4I. Gahali‐Sass5A. Moses6E. Kario7E. Ben‐Dor Cohen8J. Nicenboim9H. Ben David10K. Sudakov11A. Cohen12M. Bassan13N. B. Zak14BiomX Ltd Ness Ziona IsraelBiomX Inc Branford Connecticut USABiomX Inc Branford Connecticut USABiomX Ltd Ness Ziona IsraelBiomX Ltd Ness Ziona IsraelBiomX Ltd Ness Ziona IsraelBiomX Ltd Ness Ziona IsraelBiomX Ltd Ness Ziona IsraelBiomX Ltd Ness Ziona IsraelBiomX Ltd Ness Ziona IsraelBiomX Ltd Ness Ziona IsraelBiomX Ltd Ness Ziona IsraelBiomX Ltd Ness Ziona IsraelBiomX Ltd Ness Ziona IsraelBiomX Ltd Ness Ziona IsraelAbstract Background Topical antibiotics are frequently used to treat acne vulgaris. Their prolonged use, often for longer durations than recommended, has led to antibiotic resistance in Cutibacterium acnes (C. acnes), a bacterium implicated in acne pathophysiology. Bacteriophage (phage), which specifically target C. acnes by a different mechanism of action and do not harm potentially beneficial bacteria, may offer an alternative approach for improvement of the appearance of acne prone skin. Objectives To identify and characterize C. acnes targeting phage, carry out a comprehensive preclinical safety evaluation of phages selected for further development and examine their safety, tolerability and ability to target facial C. acnes when applied topically in a cosmetic clinical study including participants with mild‐to‐moderate acne. Methods Phages were isolated by conventional microbiological methods also used to examine their breadth of host range on different C. acnes strains and specificity to this bacterial species. Safety assessment of three selected phages was carried out by complete genomic analysis to assure the absence of undesired sequences and by ex vivo models employed to evaluate the safety, irritability and potential systemic bioavailability of phage applied topically. A randomized, controlled clinical study assessed safety, tolerability and efficacy in targeting facial C. acnes. Results Wide host range phages that also target antibiotic resistant C. acnes were identified. Their genomes were shown to be free of undesired genes. The three‐phage cocktail, BX001, was not irritant to human skin or ocular tissues in ex vivo models and did not permeate through human epidermis. In a cosmetic clinical study, topically applied BX001 was safe and well tolerated and reduced the facial burden of C. acnes. Conclusions Combined in silico and ex vivo approaches successfully predicted the observed safety and efficacy of C. acnes targeting phage when these were topically administered in a well‐controlled cosmetic clinical study.https://doi.org/10.1002/ski2.93 |
| spellingShingle | M. Golembo S. Puttagunta U. Rappo E. Weinstock R. Engelstein I. Gahali‐Sass A. Moses E. Kario E. Ben‐Dor Cohen J. Nicenboim H. Ben David K. Sudakov A. Cohen M. Bassan N. B. Zak Development of a topical bacteriophage gel targeting Cutibacterium acnes for acne prone skin and results of a phase 1 cosmetic randomized clinical trial Skin Health and Disease |
| title | Development of a topical bacteriophage gel targeting Cutibacterium acnes for acne prone skin and results of a phase 1 cosmetic randomized clinical trial |
| title_full | Development of a topical bacteriophage gel targeting Cutibacterium acnes for acne prone skin and results of a phase 1 cosmetic randomized clinical trial |
| title_fullStr | Development of a topical bacteriophage gel targeting Cutibacterium acnes for acne prone skin and results of a phase 1 cosmetic randomized clinical trial |
| title_full_unstemmed | Development of a topical bacteriophage gel targeting Cutibacterium acnes for acne prone skin and results of a phase 1 cosmetic randomized clinical trial |
| title_short | Development of a topical bacteriophage gel targeting Cutibacterium acnes for acne prone skin and results of a phase 1 cosmetic randomized clinical trial |
| title_sort | development of a topical bacteriophage gel targeting cutibacterium acnes for acne prone skin and results of a phase 1 cosmetic randomized clinical trial |
| url | https://doi.org/10.1002/ski2.93 |
| work_keys_str_mv | AT mgolembo developmentofatopicalbacteriophagegeltargetingcutibacteriumacnesforacneproneskinandresultsofaphase1cosmeticrandomizedclinicaltrial AT sputtagunta developmentofatopicalbacteriophagegeltargetingcutibacteriumacnesforacneproneskinandresultsofaphase1cosmeticrandomizedclinicaltrial AT urappo developmentofatopicalbacteriophagegeltargetingcutibacteriumacnesforacneproneskinandresultsofaphase1cosmeticrandomizedclinicaltrial AT eweinstock developmentofatopicalbacteriophagegeltargetingcutibacteriumacnesforacneproneskinandresultsofaphase1cosmeticrandomizedclinicaltrial AT rengelstein developmentofatopicalbacteriophagegeltargetingcutibacteriumacnesforacneproneskinandresultsofaphase1cosmeticrandomizedclinicaltrial AT igahalisass developmentofatopicalbacteriophagegeltargetingcutibacteriumacnesforacneproneskinandresultsofaphase1cosmeticrandomizedclinicaltrial AT amoses developmentofatopicalbacteriophagegeltargetingcutibacteriumacnesforacneproneskinandresultsofaphase1cosmeticrandomizedclinicaltrial AT ekario developmentofatopicalbacteriophagegeltargetingcutibacteriumacnesforacneproneskinandresultsofaphase1cosmeticrandomizedclinicaltrial AT ebendorcohen developmentofatopicalbacteriophagegeltargetingcutibacteriumacnesforacneproneskinandresultsofaphase1cosmeticrandomizedclinicaltrial AT jnicenboim developmentofatopicalbacteriophagegeltargetingcutibacteriumacnesforacneproneskinandresultsofaphase1cosmeticrandomizedclinicaltrial AT hbendavid developmentofatopicalbacteriophagegeltargetingcutibacteriumacnesforacneproneskinandresultsofaphase1cosmeticrandomizedclinicaltrial AT ksudakov developmentofatopicalbacteriophagegeltargetingcutibacteriumacnesforacneproneskinandresultsofaphase1cosmeticrandomizedclinicaltrial AT acohen developmentofatopicalbacteriophagegeltargetingcutibacteriumacnesforacneproneskinandresultsofaphase1cosmeticrandomizedclinicaltrial AT mbassan developmentofatopicalbacteriophagegeltargetingcutibacteriumacnesforacneproneskinandresultsofaphase1cosmeticrandomizedclinicaltrial AT nbzak developmentofatopicalbacteriophagegeltargetingcutibacteriumacnesforacneproneskinandresultsofaphase1cosmeticrandomizedclinicaltrial |